Recent Updates
Recently added Catalysts

Myomo Inc.

MYOFDA catalysts, PDUFA dates & pipeline intelligence
$0.92
▼ -0.1 · -9.91%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full MYO financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $0.6052W HIGH $1.89
Volume
438.69 K
Value Traded
427.59 K
Short % Float
3.22%
Days to Cover
5.8
-26.49%Week
-26.49%1 Month
-50.6%3 Month
+0.45%6 Month

Cash Data

Unlock MYO cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
36.85 M
EPS (TTM)
-0.38
P/E Ratio
-
Ent. Value
38.34 M
Total Shares
40.10 M
Float Shares
35.91 M
Insiders
10.45%
Institutions
34.20%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Unlock every MYO catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

MYO Catalyst Timeline

Dated clinical, regulatory and corporate events for Myomo Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Myomo Inc.

4Total events
0Upcoming
0Tier-1 (high impact)
2026 to 2026Coverage

Event history 2

●Quarterly UpdateCorporate
Myomo to report Q2 2026 financial results
▲Timing GuidancePresentation
Q3 2026 revenue guidance of $11.5M-$12.0M
Unlock the full MYO catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How MYO actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
No matching catalysts
Unlock all MYO historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

No drug pipeline

Myomo Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.

Clinical Trial Results

Readouts, endpoints and source filings for every MYO program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
Scroll for more · summaries link to the source press release
Unlock every MYO trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock MYO insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Kovelman HarryOfficer (Chief Medical Officer)Sell -15,488 90,245 held$1.27 09/11/2026
Unlock the full MYO insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
SOLEUS CAPITAL MANAGEMENT, L.P. 0 % (-100 %) 628.21 K 704.27 K
Unlock every fund holding MYO
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in MYO
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see MYO ownership
Insider and institutional ownership, quarter by quarter.

MYO Short Interest

Shares sold short, counted twice a month.

3.22%
Short % of Float
of tradable shares sold short
1.2M
Shares Sold Short
+8.6% vs prior count
5.8 High
Days to Cover
trading days of normal volume to buy every short share back
201.2K
Avg Daily Volume
the average used for days to cover
Unlock MYO short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock MYO option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live MYO option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock MYO options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How MYO ranks across every disease it competes in

Competitive Position is a premium feature
See how MYO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

MYO News

-MYO
Nov 9, 2026
MYOGeneral
▼ -9.3%on this news

Myomo Reports Third Quarter 2026 Financial and Operating Results

Myomo reported third-quarter 2026 revenue of $12.3 million, a 22% increase year-over-year. The company achieved breakeven Adjusted EBITDA and saw 54% of revenue from recurring patient sources. Myomo narrowed its full-year revenue guidance to $46-47 million, indicating positive operational progress despite a net loss of $4.2 million.

Read more →
-MYO
Nov 3, 2026
MYOConferences/Events

Myomo to Attend the 17th Annual Craig Hallum Alpha Select Conference

Myomo, Inc. will participate in the 17th Annual Craig Hallum Alpha Select Conference on November 17, 2026. Executives including CEO Paul Gudonis will hold one-on-one meetings with investors. The company specializes in wearable medical robotics that assist individuals with upper-limb paralysis.

Read more →
-MYO
Nov 2, 2026
MYOConferences/Events
▲ +6.7%on this newsshared move

Myomo to Report Third Quarter 2026 Financial Results on November 9

Myomo, Inc. will announce its financial results for Q3 2026 on November 9, 2026. The company will hold a conference call at 4:30 p.m. Eastern time to discuss the results and provide updates. Myomo specializes in wearable medical robotics to assist those with neurological disorders and upper-limb paralysis.

Read more →
-MYO
Oct 12, 2026
MYOGeneral
▼ -5.1%on this news

Myomo Appoints Mary-Katherine McClure as Chief Commercial Officer

Myomo, Inc. has appointed Mary-Katherine McClure as the new Chief Commercial Officer, effective October 12, 2026. She succeeds Micah Mitchell, who is leaving the company after a leadership transition period. McClure brings over 20 years of experience in the industry, which is expected to enhance Myomo's commercial strategies.

Read more →
-MYO
Sep 1, 2026
MYOConferences/Events

Myomo to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Myomo, Inc. has announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, at the Lotte Palace Hotel in New York. The company aims to highlight its advancements in wearable medical robotics designed for individuals with neurological disorders and upper-limb paralysis. This event is expected to enhance Myomo's visibility in the investment community.

Read more →
-MYO
Aug 5, 2026
MYOGeneral
▲ +23.6%on this news· ran to +42% by day 3

Myomo Reports Second Quarter 2026 Financial and Operating Results

Myomo, Inc. reported its financial results for Q2 2026, highlighting a revenue of $11.7 million, which surpassed expectations. The company attributes this success to an evolved go-to-market strategy aimed at enhancing its offerings for individuals with neurological disorders and upper-limb paralysis. Overall, the results indicate a positive trajectory for Myomo.

Read more →
-MYO
Jul 29, 2026
MYOConferences/Events
▲ +7.5%on this news

Myomo to Report Second Quarter 2026 Financial Results on August 5

Myomo, Inc. has announced the date for its second quarter financial results, which will be reported on August 5, 2026. The company specializes in wearable medical robotics aimed at aiding those with neurological disorders and upper-limb paralysis. A conference call will follow the report to discuss the results and provide business updates.

Read more →
-MYO
Jun 16, 2026
MYOConferences/Events
▲ +6.3%on this news

Myomo Announces Participation in iAccess Alpha Virtual Best Ideas Summer Investment Conference

Myomo, Inc. announced its participation in the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026. The event will take place on June 23-24, where CEO Paul Gudonis and CFO David Henry will present and meet with investors. A live webcast of the presentation will be available, along with a replay afterward.

Read more →
-MYO
May 14, 2026
MYOConferences/Events
▲ +5.2%on this news

Myomo Announces Participation in Upcoming Investor Conferences

Myomo, Inc. has announced its participation in two upcoming investor conferences. CEO Paul Gudonis and CFO David Henry will engage in a fireside chat at the Alliance Global Partners Annual Healthcare Company Showcase on May 20. Additionally, CFO David Henry will present at Sidoti's Virtual Micro Cap Conference on May 21, which will include one-on-one investor meetings.

Read more →
-MYO
May 13, 2026
MYOGeneral

Myomo Appoints Joseph M. Manko to its Board of Directors

Myomo, Inc. has appointed Joseph M. Manko Jr. to its Board of Directors, effective May 9, 2026. Manko brings over 25 years of experience in investment banking, private equity, and corporate strategy, including his role as Senior Principal of Horton Capital Management LLC. His addition to the board aims to support Myomo's growth strategy and enhance shareholder value, while the company continues to develop its innovative technology for patients with neurological disorders and upper-limb paralysis.

Read more →
-MYO
May 8, 2026
MYOGeneral
▼ -5%on this newsshared move

Myomo Reports First Quarter 2026 Financial and Operating Results

Myomo, Inc. reported its financial results for Q1 2026, achieving revenue of $10.1 million, a 3% increase from the previous year. The company noted a significant shift towards recurring patient revenue sources, which now account for 49% of total revenue. Operating losses decreased, and gross margins improved, indicating positive operational trends. Myomo anticipates continued revenue growth in the upcoming quarter.

Read more →
-MYO
May 4, 2026
MYOGeneral

Myomo Announces Availability of MyoPro at Ottobock Care Clinics in the U.S.

Myomo, Inc. has announced that its MyoPro powered arm brace will be available at Ottobock Care clinics across the U.S. This initiative aims to assist individuals suffering from upper extremity impairments due to conditions such as stroke and brachial plexus injury. The collaboration enhances Ottobock Care's offerings in neuro-robotic solutions for patients.

Read more →
-MYO
May 1, 2026
MYOConferences/Events

Myomo to Report First Quarter 2026 Financial Results on May 7

Myomo, Inc. will announce its financial results for the first quarter of 2026 on May 7. The company specializes in wearable medical robotics for individuals with neurological disorders. A conference call will follow the announcement, allowing management to discuss results and answer questions from participants.

Read more →
-MYO
Apr 20, 2026
MYOGeneral

Myomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient Engagement

Myomo, Inc. has launched the Myomo Mobile App to enhance the MyoPro experience for clinicians and patients. This app aims to provide a more intuitive and connected care process, allowing clinicians to customize settings and monitor patient usage effectively. The initiative is expected to improve patient engagement and care management.

Read more →
-MYO
Apr 16, 2026
MYOGeneral

Myomo Appoints William J Febbo to its Board of Directors

Myomo, Inc. has appointed William J Febbo to its Board of Directors effective April 14, 2026. Febbo brings over 30 years of experience in healthcare and technology-driven businesses, which is expected to support Myomo's strategic initiatives for 2026 and beyond. He is recognized for his successful track record in guiding organizations through growth and transformation. This addition to Myomo's board is viewed as a crucial step towards strengthening the company's position in the wearable medical robotics market.

Read more →
-MYO
Mar 9, 2026
MYOGeneral

Myomo and Elevance Health Agree to Contract for Multi-State Network Participation

Myomo, Inc. has announced a contract with Elevance Health to participate in a multi-state network. This agreement will include Anthem-affiliated plans and is expected to roll out market-by-market through Q2 2026. The deal will increase Myomo's covered lives to over 80 million, enhancing its market presence.

Read more →
-MYO
Mar 9, 2026
MYOGeneral

Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Myomo, Inc. announced its financial results for Q4 and full year 2025, reporting a revenue of $11.4 million for the quarter and $40.9 million for the year. The company emphasized growth from recurring patient sources, which constituted 42% of its fourth quarter revenue. Myomo recorded its highest number of authorizations and orders in the fourth quarter and introduced a revenue guidance for 2026 of $43 million to $46 million. However, the company faced challenges with a 6% decline in quarterly revenue compared to the same period last year and increased operating losses.

Read more →
-MYO
Mar 2, 2026
MYOConferences/Events

Myomo to Report Fourth Quarter 2025 Financial Results on March 9

Myomo, Inc. will announce its financial results for Q4 and the full year of 2025 on March 9, 2026. The company, known for its wearable medical robotics, will hold a conference call at 4:30 p.m. ET to discuss the results and provide a business update. This event reflects the company's commitment to transparency.

Read more →
-MYO
Nov 10, 2025
MYOConferences/Events
▲ +7.4%on this newsshared move

Myomo Reports Third Quarter 2025 Financial and Operating Results

Myomo, Inc. reported its financial results for the third quarter of 2025, revealing revenue of $10.1 million, marking a 10% rise compared to the same period last year. The company noted its highest number of authorizations and orders, totaling 229, and reiterated its full-year revenue guidance of $40 to $42 million. However, Myomo faced challenges as it recorded an operating loss of $3.5 million, which is larger than the prior year's loss, alongside a decrease in gross margin due to increased costs. Despite these challenges, Myomo is optimistic about its new strategy to enhance patient referrals through its MyoConnect program.

Read more →
-MYO
Nov 3, 2025
MYOConferences/Events

Myomo to Report Third Quarter 2025 Financial Results on November 10

Myomo, Inc. will announce its financial results for Q3 2025 on November 10, 2025. The company specializes in wearable medical robotics aimed at aiding those with neurological disorders and upper-limb paralysis. A conference call will follow the announcement to discuss results and provide updates.

Read more →

About Myomo Inc.

Boston, MA 195 employees myomo.com
Headquarters137 PORTLAND STREET, BOSTON, MA, 02114
BIOPHARMAWATCH ELITE
Trade the next MYO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime